All In Biotech

Drug Trial Radar · NCT04064632

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection

Multicenter, National, Prospective, Open Label, Randomized, Pilot, Proof-of-concept Study on the Use of Rilpivirine Plus Darunavir/Cobicistat as Substitutive Agents in Virologic Suppressed Patients

Last checked: Nov 19, 2026Latest source record: Aug 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,609 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,609

Actual

Start

Feb 1, 2017

Primary completion

Jun 13, 2019

Study completion Nov 30, 2019

Sponsor

Lead sponsor
A.O. Ospedale Papa Giovanni XXIIIAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
San Raffaele University Hospital, Italy
First posted
Aug 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates efficacy and safety of rilpivirine as substitutive agent for the nucleosidic backbone of HAART in virologic suppressed patients when combined with cobicistat-boosted darunavir.

Conditions

  • HIV Infection

Interventions

  • Rilpivirine + darunavir/cobicistatDrug

    Switch to a dual ART

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. clinical responseTime frame: 24 weeks
  2. Virological responseTime frame: 24 weeks
  3. clinical responseTime frame: 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Antiviral Therapy Unit, Ospedali Riuniti

    Bergamo, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.